Long-term data show that frontline zanubrutinib significantly improved second progression-free survival (PFS2) and preserved the effectiveness of subsequent BCL2 inhibitor–based therapies compared with bendamustine-rituximab in treatment-naive CLL/SLL.
New data from the phase 3 DeLLphi-304 trial suggest tarlatamab significantly improves intracranial efficacy outcomes, CNS progression-free survival, and overall survival in patients with relapsed small cell lung cancer (SCLC) and baseline brain metastases.
Phase 3 frontMIND phase 3 trial data show tafasitamab plus lenalidomide with R-CHOP boosts PFS and has manageable safety in high-risk newly diagnosed DLBCL.
Elranatamab monotherapy produced a 92% overall response rate and a 45% complete response rate in patients with high-risk smoldering multiple myeloma, supporting the potential of BCMA-directed bispecific antibody therapy as an early intervention strategy before progression to active disease.
Cross-trial data from more than 6000 administrations show that a subcutaneous isatuximab on-body injector was highly reliable and well tolerated.
IDEAL trial data show iberdomide quadruplet therapy drives high response rates and rising MRD negativity in newly diagnosed multiple myeloma.
Phase 3 MajesTEC-9 data show that teclistamab monotherapy significantly improved PFS, OS, and depth of response compared with standard PVd or Kd regimens.
Darovasertib plus crizotinib boosts survival signals and response rates in HLA-A2–negative metastatic uveal melanoma, with manageable safety.
Results from the SERENA-6 trial show that an early switch to the oral selective estrogen receptor degrader camizestrant combined with a CDK4/6 inhibitor improves progression-free survival 2, delays chemotherapy, and preserves quality of life.
The FDA granted Priority Review to the NDA for bezuclastinib plus sunitinib in previously treated advanced gastrointestinal stromal tumors (GIST).
A real-world study presented at ASCO 2026 found that early intravenous immunoglobulin administration within 4 weeks of starting talquetamab was associated with significantly lower infection rates and reduced 1-year mortality in patients with relapsed or refractory multiple myeloma.
Updated results from a phase 1 study showed that KLN-1010 produced reduced MRD-negative responses in all treated patients with RRMM.
Data presented at ASCO 2026 show giredestrant plus palbociclib extends PFS in ER+/HER2– metastatic breast cancer; FDA approval is on the horizon.
ASCENT-04 updated data show sacituzumab govitecan plus pembrolizumab extends benefit past progression in PD-L1+ metastatic TNBC.
Findings from the SWOG S2001 trial show that pembrolizumab plus olaparib did not significantly improve progression-free survival compared with olaparib alone as maintenance therapy in patients with metastatic pancreatic cancer harboring germline BRCA1/2 mutations.
Final results from the CEPHEUS trial showed that daratumumab plus VRd produced deeper, more durable responses and prolonged survival.
Elizabeth Budde, MD, discusses the phase 3 data behind the mosunetuzumab plus polatuzumab vedotin combination in the SUNMO trial.
Electronic patient-reported outcome (ePRO) monitoring platforms may improve symptom management, reduce hospitalizations, and help patients remain on cancer therapy longer through earlier intervention and continuous remote support.
ASCO 2026: Daraxonrasib boosts survival and PFS in metastatic pancreatic cancer vs chemotherapy, with better tolerability and quality-of-life preservation.
ASCO 2026 data show encorafenib plus cetuximab with FOLFIRI boosts response and PFS in BRAF V600E mCRC, complementing FOLFOX.
Jessica Paulus, ScD, discusses emerging real-world evidence suggesting GLP-1 receptor agonists may be associated with improved survival outcomes across several cancer types, while emphasizing the need for prospective clinical research.
Phase 3 SARC041 data show that abemaciclib sharply extends progression-free survival in advanced dedifferentiated liposarcoma, hinting at a new standard.
The trial met both dual primary end points of pathologic complete response and metastasis-free survival.
SARC041 data shows the clinical benefits associated with abemaciclib in the treatment of patients with incredibly rare diseases.
Apalutamide plus androgen deprivation therapy significantly increased the curative success of radical prostatectomy in patients with localized prostate cancer.
At ASCO 2026, GLORA investigators report on lisaftoclax as an addition to BTK inhibitors to deepen responses and delay progression in high-risk CLL/SLL.
Seven-year CROWN trial update shows lorlatinib delivers durable progression-free survival and strong brain control in ALK-positive NSCLC.
APP-led benign hematology consult programs helped community oncology practices significantly reduce time to first appointment while strengthening interdisciplinary collaboration with pharmacists and physicians.
DREAMM-9 data show belantamab mafodotin in TI NDMM delivers high responses, with longer dosing improving eye safety and quality of life.
Enfortumab vedotin combination delivers lasting complete responses in la/mUC.
